KRAS and non-small cell lung carcinoma: The median OS, regardless of treatment type, of the patients with a KRAS G12C NSCLC was 15.5 months (95% CI: 13.6–18.4) versus 14.0 months (95% CI: 11.2–15.7) for KRAS non-G12C (p = 0.67; Fig. 2).